Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Boule Diagnostics AB's Revenue for the
three
months ended in Mar. 2026 was $10.91 Mil. Boule Diagnostics AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was $13.18 Mil.
Hence, Boule Diagnostics AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.83.
Boule Diagnostics AB (OTCPK:BDABF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Boule Diagnostics AB Receivables Turnover Related Terms
Boule Diagnostics AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BDABF vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (BDABF) has a Receivables Turnover of 0.83 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Boule Diagnostics AB and its competitors. According to the industry distribution chart, Boule Diagnostics AB ranks #623 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 76.6%.
Is Boule Diagnostics AB's Receivables Turnover too high?
Boule Diagnostics AB's current Receivables Turnover is 0.83. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Boule Diagnostics AB's value of 0.83 is 84.9% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #623 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #623 out of 813 companies for Receivables Turnover. This places Boule Diagnostics AB in the lower half of its industry. The industry median Receivables Turnover is 5.51. Boule Diagnostics AB's value of 0.83 is 84.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Receivables Turnover of 0.83 is 84.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Receivables Turnover is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (BDABF) has a current Receivables Turnover of 0.83. The stock's GF Value™ is $14.73, compared to a current price of $7.84 — trading 46.8% below its estimated fair value. The current Receivables Turnover is 0.83 and 84.9% below the Medical Devices & Instruments industry median of 5.51. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Boule Diagnostics AB (BDABF), the current Receivables Turnover is 0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (BDABF) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of $7.84 is trading 46.8% below its estimated GF Value™ of $14.73.
Key valuation signals for BDABF:
Receivables Turnover: 0.83
GF Value™: $14.73 vs. price of $7.84 (46.8% below fair value)
Industry Position: 84.9% below the Medical Devices & Instruments median (#623 of 813)
No single metric tells the full story. See the BDABF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for BDABF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDABF has been successfully added to your 
